Sunday, October 12, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

FibroGen Shares Extend Decline Amid Mixed Analyst Outlook

Dieter Jaworski by Dieter Jaworski
October 12, 2025
in Analysis, Pharma & Biotech, Trading & Momentum
0
FibroGen Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

FibroGen’s stock continued its downward trajectory on Friday, closing at $10.55 after declining 3.74% during the trading session. This latest drop extends a troubling pattern for the biotechnology firm, which has now shed 14.3% of its value over the past ten trading days. The negative momentum was further amplified by StockInvest.us, which revised its rating on the company from “Hold” to “Sell.”

Trading Activity and Technical Indicators

Friday’s session opened with FibroGen shares trading at $10.96, but the stock quickly lost ground, dipping to an intraday low of $10.29 before settling at the closing price of $10.55. Trading volume saw an uptick, reaching 66,000 shares. From a technical perspective, the outlook remains bearish, with both short-term and long-term moving averages signaling continued downward pressure.

The current market sentiment presents a stark contrast to analyst expectations. While StockInvest.us has adopted a negative stance, other market researchers maintain an average price target of $43.00 per share. This significant gap between the stock’s present valuation and long-term projections has created substantial uncertainty among investors.

Should investors sell immediately? Or is it worth buying FibroGen?

Clinical Developments and Financial Position

Despite the challenging market performance, FibroGen continues to advance its clinical pipeline. The company received positive regulatory feedback from the FDA in August regarding Roxadustat for anemia treatment and plans to submit its Phase 3 protocol before the current quarter concludes. Additionally, September marked the initiation of a Phase 2 trial for FG-3246 in prostate cancer patients.

Financially, the company strengthened its position through the divestiture of FibroGen China to AstraZeneca, a transaction valued at approximately $210 million. This strategic move has extended the company’s liquidity runway through 2028. However, second-quarter results disappointed market participants, with FibroGen reporting a net loss of $13.7 million while missing expectations for both earnings per share and revenue.

Critical Quarter Ahead

All eyes now turn to November, when FibroGen will release its third-quarter results. This upcoming report will provide crucial insight into how the China divestiture has impacted the company’s financial statements. From a technical standpoint, support appears to be forming at the $9.25 level, while resistance barriers stand at $11.28 and $11.59. Should the stock remain below these technical thresholds, the current downtrend could potentially accelerate.

Ad

FibroGen Stock: Buy or Sell?! New FibroGen Analysis from October 12 delivers the answer:

The latest FibroGen figures speak for themselves: Urgent action needed for FibroGen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 12.

FibroGen: Buy or sell? Read more here...

Tags: FibroGen
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

PayPal Stock
E-Commerce

PayPal Shares Plunge Ahead of Earnings Report

October 12, 2025
Charter Communications Stock
Analysis

Charter Communications Faces Critical Test Amid Customer Exodus and Legal Threats

October 12, 2025
Red Cat Holdings Stock
Analysis

Defense Tech Firm Red Cat Reels Following Short Seller Allegations

October 12, 2025
Next Post
US Global Investors Stock

Gold Fund Manager's Shares Defy Sector Strength Amid Political Gridlock

Rockwell Medical Stock

Rockwell Medical Shares Plunge Amid Intensifying Sell-Off

Hydrofarm Holdings Inc Stock

Hydrofarm Navigates Turbulent Waters Amid Financial Restructuring

Recommended

Hannover Re Stock

Hannover Re Overhauls Dividend Strategy with Major Payout Increase

6 days ago

Wedbush Analyst Upgrades Jack In The Box to Outperform

2 years ago

KEYTRUDA Shows Promising Results as Adjuvant Therapy in Urothelial Carcinoma

2 years ago
Technology Data analytics stock Trading

Celesticas Stock Soars on Impressive Q4 Results and Positive Q1 Projections

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Defense Tech Firm Red Cat Reels Following Short Seller Allegations

Navitas Semiconductor: A Stock Divided Between AI Promise and Financial Reality

Fannie Mae Shares Face Critical Test After Stellar Rally

Hercules Capital Shares: A Battle Between Strong Fundamentals and Market Pessimism

SunPower Shares Continue Downward Spiral as Retention Costs Raise Concerns

Wall Street Analysts Rally Behind Water Technology Leader Xylem

Trending

Nio Stock
AI & Quantum Computing

Leadership Shakeup Rattles Nio’s Autonomous Driving Ambitions

by Felix Baarz
October 12, 2025
0

Chinese electric vehicle manufacturer Nio faces mounting pressure, though the concern stems not from disappointing sales figures...

PayPal Stock

PayPal Shares Plunge Ahead of Earnings Report

October 12, 2025
Charter Communications Stock

Charter Communications Faces Critical Test Amid Customer Exodus and Legal Threats

October 12, 2025
Red Cat Holdings Stock

Defense Tech Firm Red Cat Reels Following Short Seller Allegations

October 12, 2025
Navitas Semiconductor Corporation Stock

Navitas Semiconductor: A Stock Divided Between AI Promise and Financial Reality

October 12, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Leadership Shakeup Rattles Nio’s Autonomous Driving Ambitions
  • PayPal Shares Plunge Ahead of Earnings Report
  • Charter Communications Faces Critical Test Amid Customer Exodus and Legal Threats

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com